Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Baader Bank Aktiengesellschaft

Baader Bank Aktiengesellschaft trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 71.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,562 shares of the biopharmaceutical company’s stock after selling 6,327 shares during the quarter. Baader Bank Aktiengesellschaft’s holdings in Regeneron Pharmaceuticals were worth $1,439,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Cove Private Wealth LLC grew its stake in Regeneron Pharmaceuticals by 8.7% during the 3rd quarter. Cove Private Wealth LLC now owns 500 shares of the biopharmaceutical company’s stock valued at $281,000 after purchasing an additional 40 shares in the last quarter. Wealthfront Advisers LLC boosted its stake in shares of Regeneron Pharmaceuticals by 28.7% during the 3rd quarter. Wealthfront Advisers LLC now owns 5,940 shares of the biopharmaceutical company’s stock valued at $3,340,000 after buying an additional 1,325 shares during the last quarter. AlTi Global Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 11.8% during the 3rd quarter. AlTi Global Inc. now owns 464 shares of the biopharmaceutical company’s stock valued at $261,000 after buying an additional 49 shares during the last quarter. Oppenheimer & Co. Inc. grew its position in shares of Regeneron Pharmaceuticals by 7.2% during the third quarter. Oppenheimer & Co. Inc. now owns 23,714 shares of the biopharmaceutical company’s stock worth $13,334,000 after buying an additional 1,597 shares in the last quarter. Finally, Linden Thomas Advisory Services LLC increased its stake in shares of Regeneron Pharmaceuticals by 4.2% in the third quarter. Linden Thomas Advisory Services LLC now owns 4,413 shares of the biopharmaceutical company’s stock worth $2,481,000 after buying an additional 178 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at $1,362,400. This represents a 46.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.02% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Sunday. Morgan Stanley boosted their target price on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the stock an “equal weight” rating in a research report on Monday, February 2nd. Zacks Research cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. Canaccord Genuity Group lifted their price target on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Finally, Bank of America raised Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and boosted their price objective for the company from $627.00 to $860.00 in a report on Wednesday, January 7th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $793.81.

Regeneron Pharmaceuticals Trading Down 3.3%

NASDAQ REGN opened at $754.91 on Wednesday. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $821.11. The company has a 50-day simple moving average of $758.15 and a 200-day simple moving average of $661.69. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. The firm has a market capitalization of $79.34 billion, a PE ratio of 18.16, a price-to-earnings-growth ratio of 2.10 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the prior year, the business earned $12.07 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 2.5% on a year-over-year basis. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be given a dividend of $0.94 per share. The ex-dividend date is Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s payout ratio is presently 8.47%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.